Taylor & Francis

First-line management of unresectable hepatocellular carcinoma: clinical perspectives from the CheckMate 9DW study by Taylor & Francis Group

In this podcast episode, the speakers discuss how the findings from the EMBARK clinical trial could translate into real world practice.

This podcast focuses on the real-world implications of these EMBARK findings for clinical practice.

This podcast features two of the investigators from the international, randomized, Phase III EMBARK trial (NCT02319837) in conversation.

EMBARK evaluated the efficacy and safety of enzalutamide plus androgen deprivation therapy and enzalutamide monotherapy, as compared with androgen deprivation therapy alone, in patients with nonmetastatic castration-sensitive prostate cancer and biochemical recurrence at high risk for metastasis.

In this podcast, the second in the EMBARK series, the speakers discuss the key efficacy and safety findings from the trial, consider some of the patient-reported outcomes and their implications for quality of life, and review some of the implications for clinical practice.

In this interview, discover discuss key findings from the DESTINY-Breast09 trial and their implications for clinical practice, including practical advice for oncologists exploring treatment sequencing strategies with T-DXd.

Meet Giorgi Kobidze, your 2026 BRSA finalist.

Meet Richa Pandey, your 2026 BRSA finalist.

Enzalutamide in biochemically recurrent prostate cancer: design and rationale of the EMBARK study by Taylor & Francis Group

Meet Dakshat Trivedi, your 2026 BRSA finalist.

Meet Ethan Sanford, your 2026 BRSA finalist.